Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Zenyaku gets Japanese rights to blisibimod from Anthera

Executive Summary

Anthera Pharmaceuticals Inc. granted Zenyaku Kogyo Co. Ltd. exclusive rights to develop and sell subcutaneous blisibimod in Japan for IgA nephropathy and systemic lupus erythematosus. The deal also includes an option for rights in additional Asian countries, including China, Hong Kong, Singapore, Taiwan, the Philippines, Thailand, Malaysia, Vietnam, Indonesia, and South Korea.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register